SF3A3 and colorectal cancer: Furthermore, to explore whether SF3A3 could be considered as a potential drug target for CRC clinical treatment, we referred to the DrugBank database and found that the SF3A3 gene is a putative target for PEITC, which has been reported to inhibit cancer cell growth through cell-cycle arrest and induction of apoptotic events in various human cancer cells models including colorectal cancer cells30, prostate cancer cells31, osteogenic sarcoma cells32, and oral cancer cells33.